Company: SMNR
Filing Date: 2025-04-21
Form Type: CORRESP
Source: 0001193125-25-087365
Chunk: 0

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-21
Form: CORRESP
Chunk 0
---
Denali Capital Acquisition Corp. April 21, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Franklin Wyman, Angela Connell, Jessica Dickerson, Joe McCann

| Re: | Denali Capital Acquisition Corp. |

Semnur Pharmaceuticals, Inc. Registration Statement on Form S-4 Filed November 6, 2024 File No. 333-283019 Ladies and Gentlemen: Denali Capital Acquisition Corp., a Cayman Islands exempted company (the “ Company”), files herewith Amendment No. 1 (“ Amendment No. 1”) to the above-referenced registration statement on Form S-4filed on November 6, 2024 (the “ Registration Statement”). Set forth below are the responses of the Company to the comments of the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (the “ Staff”) with respect to the Registration Statement contained in the Staff’s letter dated December 11, 2024 (the “ Comment Letter”). For ease of reference, each comment contained in the Comment Letter is printed below and is followed by the Company’s response. All page references in the responses set forth below refer to page numbers in Amendment No. 1. All capitalized terms used but not defined in this response letter have the meanings ascribed to such terms in Amendment No. 1. Cover Page

| 1. | Please revise the prospectus cover page to include disclosure highlighting the number and each type of                                                                                                                                                
 security being registered, including disclosure as to how you arrived at the number of securities being registered. In this regard, we note from the header on the prospectus cover page that you are registering 262,684,337 shares of common stock, 
 524,622 units, 6,000,000 shares of Series A Preferred Stock, and 8,760,000 warrants of New Semnur.                                                                                                                                                    |

Response: The Company respectfully advises the Staff that it has revised the disclosure on pages ii-iii of the prospectus cover page of Amendment No. 1 to include the requested disclosure.

U.S. Securities and Exchange Commission April 21, 2025

| 2. | On page i, you state that holders of Denali Class A Ordinary Shares will be asked to approve and                                                                                                                                            
 adopt the Merger Agreement. With reference to the disclosure on page 46